Skin Sparing Mastectomy and Immediate Breast Reconstruction With Latissimus Dorsi Flap After Neoadjuvant Chemotherapy and Radiotherapy (M-RIC)

NCT ID: NCT01199354

Last Updated: 2011-06-09

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE2

Total Enrollment

80 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-07-31

Study Completion Date

2017-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of the study is to evaluate the feasibility and morbidity of skin sparing mastectomy and immediate breast reconstruction with latissimus dorsi flap after neoadjuvant chemotherapy and radiotherapy in invasive breast carcinoma.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Breast Carcinoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Mastectomy, preservation of the skin envelope,followed by immediate reconstruction with autologous latissimus dorsi flap.

Mastectomy, preservation of the skin envelope, removal of the nipple-areolar complex and dissection of the axillary lymph nodes followed by immediate reconstruction with autologous latissimus dorsi flap with or without prosthesis.

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Women \< 75 year old
* Invasive breast carcinoma, indication for mastectomy
* Women Health Organization (WHO) score of 0 and 1, primary chemotherapy, external radiotherapy performed less than 8 week earlier...

Exclusion Criteria

* Women older than 75
* Metastatic breast carcinoma
* Antecedents of previously treated homolateral breast carcinoma
* Documented cancer progression
* Smoker at the moment of the indication surgery
* Known diabetes, neoadjuvant hormonal treatment...
Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Clinique Clementville

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Clinique Clementville

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Cécile Zinzindhoue

Role: PRINCIPAL_INVESTIGATOR

Clinique Clementville

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Polyclinique Urbain V

Avignon, , France

Site Status NOT_YET_RECRUITING

Polyclinique Urbain V

Avignon, , France

Site Status NOT_YET_RECRUITING

Centre Jean Perrin

Clermont-Ferrand, , France

Site Status NOT_YET_RECRUITING

Groupe Hospitalier Mutualiste Clinique les Eaux Claires

Grenoble, , France

Site Status NOT_YET_RECRUITING

Centre Léon Bérard

Lyon, , France

Site Status NOT_YET_RECRUITING

Institut Paoli Calmettes

Marseille, , France

Site Status NOT_YET_RECRUITING

Institut Paoli Calmettes

Marseille, , France

Site Status NOT_YET_RECRUITING

Clinique Clementville

Montpellier, , France

Site Status RECRUITING

CRLCC Val d'Aurelle

Montpellier, , France

Site Status NOT_YET_RECRUITING

Clinique Belledonne

Saint-Martin-d'Hères, , France

Site Status NOT_YET_RECRUITING

Institut Claudius Regaud

Toulouse, , France

Site Status NOT_YET_RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

France

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Magali Lacroix

Role: CONTACT

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Bernard Miramand

Role: primary

Nicolas Sterkers

Role: primary

Jacques Dauplat

Role: primary

Philippe Gabelle

Role: primary

Catherine Bouteille

Role: primary

Gilles Houvenaeghel

Role: primary

Monique Cohen

Role: primary

Pierre Berrand

Role: primary

Marian Gutowski

Role: primary

Raoul Payan

Role: primary

Hélène Charitansky

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CLEM-01

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Delayed-Immediate Breast Reconstruction
NCT00473122 COMPLETED PHASE2